Richard Warren

Featured in: Favicon

wiley.com (+1) Favicon

mdpi.com

scmp.com

futuremedicine.com Favicon

jofskin.org Favicon

twill.health Favicon

care.twill.health

Articles

Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis

May 3, 2024 | mdpi.com | Elan May Shellard |Stephen Eyre |Richard Warren |Elan May

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Mar 7, 2024 | onlinelibrary.wiley.com | Bruce E. Strober |Andrew Blauvelt |Richard Warren |Kim A. Papp

INTRODUCTION The Janus kinase (JAK)-signal transducer and activator of transcription pathways play a major role in cytokine signalling in normal cellular processes and in immune-mediated diseases such as psoriasis.1, 2 JAK1,2,3 inhibitors are efficacious in patients with moderate-to-severe plaque psoriasis; however, JAK1,2,3 inhibitors are also associated with creatine phosphokinase (CPK) elevations, hyperlipidaemia and minimal hematologic abnormalities.3, 4 Therefore, it is important to...
Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Nov 13, 2023 | jofskin.org | April Armstrong |Mark Lebwohl |Richard Warren |Howard Sofen

1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736. 2. Sotyktu [package insert]. Princeton, NJ: Bristol Myers Squibb; September 2022. 3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023. 4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022. 5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022. 6. Sotyktu [product monograph].
Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Nov 13, 2023 | jofskin.org | Diamant Thaçi |Mark Lebwohl |Richard Warren |Leon Kircik

1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736. 2. Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb; September 2022. 3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023. 4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022. 5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022. 6. Sotyktu [product monograph].
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary

May 7, 2023 | futuremedicine.com | April Armstrong |Melinda Gooderham |Richard Warren |Kim A. Papp

ImmunotherapyAhead of PrintPlain Language Summary of PublicationOpen Access, , , , , , , , , , , , , , & AbstractWhat is this summary about? This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-1, which looked at a new treatment called deucravacitinib for plaque psoriasis. Plaque psoriasis appears on the body as round or oval raised patches (called plaques) typically covered by scales.
Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Mar 13, 2023 | jofskin.org | Mark Lebwohl |Richard Warren |Howard Sofen |Shinichi Imafuku

Main Article Content Keywords psoriasis, deucravacitinib, tyrosine kinase 2, phase 3 clinical trial, efficacy, long-term Abstract Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the pivotal phase 3 POETYK PSO-1 trial, deucravacitinib was superior to placebo and apremilast...
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial | SKIN The Journal of Cutaneous Medicine

Mar 13, 2023 | jofskin.org | Jerry Bagel |East Windsor |April Armstrong |Richard Warren

Main Article Content Keywords psoriasis, deucravacitinib, tyrosine kinase 2, phase 3 clinical trial, efficacy Abstract Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib was significantly more efficacious than placebo or apremilast and was well tolerated in previous reports from the phase...

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Richard Warren

Articles

Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary

Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial | SKIN The Journal of Cutaneous Medicine

Contact details

Emails

Socials & Sites